Extended-release gabapentin in post-herpetic neuralgia

Bibliography

• Doggrel SA. Pregabalin or morphine and gabapentin for neuropathic pain. Expert Opin Pharmacother 2005;12:2535-9
   Google Scholar
• Bader MS, McKinsey DS. Viral infections in the elderly: the challenges of managing herpes zoster, influenza, and RSV. Postgrad Med 2005;118:45-54
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Centre for Reviews and Dissemination 2004. NHS Economic Evaluation Database. Available from: http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?View=Full&ID=22001006577 [Last accessed 18 September 2011]
   Google Scholar
• Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997;13:327-31
   PubMed Web of Science ®Google Scholar
• Guidelines from the US Agency for Healthcare Research and Quality. Available from: http://www.guideline.gov/content.aspx?id=11724 [Last accessed 17 August 2011]
   Google Scholar
• Dworkin RH, O'Connor AB, Backonja M, Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-51
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O'Connor AB, Audette J, Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(3 Suppl):S3-14
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, The European Federation of Neurological Societies guidelines for the pharmacological treatment of neuropathic pain. 2010 revision. Eur J Neurol 2010;17:1113-23
   PubMed Web of Science ®Google Scholar
• Eroglu C, Allen NJ, Susman MW. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 2009;139:380-92
   PubMed Web of Science ®Google Scholar
• Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharma Res 1993;10:276-81
   Web of Science ®Google Scholar
• Gordi T, Hou E, Kasichayanula S, Berner B. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther 2008;30:909-16
   PubMed Web of Science ®Google Scholar
• Gusler G, Berner B, Chau M, Padua A. Optimal polymer mixtures for gastric retentive tablets. 2004;US6723340
   Google Scholar
• Berner B, Louie Helm J. Tablet shapes to enhance gastric retention of swellable controlled release oral dosage forms. 2002;US6488962
   Google Scholar
• Wallace MS, Irving G, Cowles VE. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Investig 2002;30:765-76
   Google Scholar
• Jensen MP, Chiang YK, Wu J. Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. Clin J Pain 2009;25:286-92
   PubMed Web of Science ®Google Scholar
• Irving G, Jensen M, Cramer M, Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain 2009;25:185-92
   PubMed Web of Science ®Google Scholar
• Chen C, Cowles VE, Hou E. Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate-release formulation and effect of dose escalation and food. J Clin Pharmacol 2011;51:346-58
   PubMed Web of Science ®Google Scholar
• Sang CN, Sathyanarayana R, Carter FJ, Sweeney M. Extended release for the once-daily treatment of post herpetic neuralgia. Poster presented at the International Association for the Study of Pain, 13th World Congress on Pain; 29 August – 2 September 2010; Montreal, Canada
   Google Scholar
• Sweeney M, Sathyanarayana R. Efficacy and tolerability of once-daily gabapentin for the treatment of postherpetic neuralgia in patients at least 65 years old. Poster presented at the Society of General Internal Medicine 34th Annual Meeting; 4 – 7 May 2011; Phoenix, AZ, USA
   Google Scholar
• ARUP Laboratory Test Directory. National Reference Laboratory. Gabapentin. Available from: http://www.aruplab.com/guides/ug/tests/0090057.jsp [Last accessed 19 September 2011]
   Google Scholar
• Liu-Seifert H, Shuyu Zhang S, D'Souza D, A closer look at the baseline-observation-carried-forward (BOCF). Patient Prefer Adherence 2010;4:11-16
   PubMed Web of Science ®Google Scholar
• Saha C, Jones M. Bias in the last observation carried forward method under informative dropout. J Stat Plan Inference 2009;139:246-55
   Web of Science ®Google Scholar
• Summary of NDA 22-516 Cymbalta for Treatment of Chronic Pain. FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Research, 2010. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM222701.pdf [Last accessed 19 September 2011]
   Google Scholar
• Depomed Press Release. Depomed will engage in mediation to resolve dispute with Abbott; Comments on DM-1796 regulatory status and orphan drug designation. Available from: http://investor.depomedinc.com/phoenix.zhtml?c=97276&p=irol-newsArticle&ID=1516964&highlight= [Last accessed 19 September 2011]
   Google Scholar
• Depomed Press Release. Depomed announces receipt of a $48 million milestone payment for the approval of GRALISE(TM). Available from: http://investor.depomedinc.com/phoenix.zhtml?c=97276&p=irol-newsArticle&ID=1533487&highlight= [Last accessed 19 September 2011]
   Google Scholar
• Depomed Press Release. Depomed announces US Food and Drug Administration approval of GRALISE(TM) (gabapentin) once-daily tablets for treatment of post-herpetic neuralgia. Available from: http://investor.depomedinc.com/phoenix.zhtml?c=97276&p=irol-newsArticle&ID=1521435&highlight= [Last accessed 19 September 2011]
   Google Scholar
• Wesche D, Bockbrader H. A pharmokinetic comparison of pregabalin and gabapentin. J Pain 2007;6:S29
   Google Scholar
• Attal N, Cruccu G, Baron R, European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-23
   PubMed Web of Science ®Google Scholar